A potential cure for HIV, developed by pioneering research scientist Dr. Serhat Gumrukçu, Director of the Seraph Research Institute (SRI), and his team have successfully completed the Pre-Investigational New Drug (IND) process for the U.S. Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER).
| LOS ANGELES, Oct. 19, 2021 /PRNewswire/ -- (NASDAQ: ENOB) − A potential cure for HIV, developed by pioneering research scientist Dr. Serhat Gumrukçu, Director of the Seraph Research Institute (SRI), and his team have successfully completed the Pre-Investigational New Drug (IND) process for the U.S. Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER). “We are extremely encouraged by this step forward from the FDA, in finding a cure for HiV,” says Dr. Serhat Gumrukçu. The submission to the FDA was based on promising results achieved by a 54-year-old man living with HIV, who was unable to sustain HIV viral load suppression with antiviral therapy (ART). Once the patient stopped taking ART, and began using the new innovative SRI treatment, his HIV infection blood levels were controlled more effectively for 365 consecutive days. “We’ve been dedicated to supporting the HIV community for many years now,” says Dr. Gumrukçu. “We are extremely encouraged by this step forward from the FDA, in finding a cure for HIV.” Dr. Gumrukçu is also co-founder and inventor of Enochian BioSciences, which holds the exclusive license for the product. “If proven to be effective, [this therapy] could offer hope to many who would like to have alternatives to daily treatment, which can be costly and difficult to maintain,” says Dr. Peter Piot, the former head of UNAIDS and the London School of Hygiene and Tropical Medicine in London. About Serhat Gumrukçu, MD, PhD Dr. Serhat Gumrukçu is the Executive Director and Director of Translational Research at the Seraph Research Institute, based in Los Angeles. His current research on infectious diseases focuses on creating new approaches and mechanisms of actions in antiviral therapies through co-opting virus-specific components of viral replication machinery, on viruses including SARS-CoV-2, HIV, HBV, influenza and Ebola. He was recently appointed to the board of The Alliance of Housing and Healing, which recently merged with AIDS Project Los Angeles (APLA). About Seraph Research Institute (SRI) About Enochian BioSciences, Inc.
SOURCE Seraph Research Institute |
View original content:
